This limited efficacy stems from multiple resistance mechanisms: (a) EZH2-mediated epigenetic silencing of tumor suppressors (e.g., RB1) promotes chemoresistance [13], and (b) cancer stem cell populations maintain treatment-refractory properties through sustained Wnt/β-catenin pathway activation [125]. The gene discussed is RB1; the disease is cancer.